UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

A month af­ter post­ing pos­i­tive top-line da­ta from their first Phase III tri­al of the IL-17A/17F in­hibitor bimek­izum­ab, Bel­gium’s UCB says they’ve added more up­beat re­sults from their sec­ond late-stage test in mod­er­ate-to-se­vere plaque pso­ri­a­sis.

That leaves the com­pa­ny on track for reg­u­la­to­ry sub­mis­sions in the mid­dle of next year, says CMO Iris Loew-Friedrich.

Their drug beat out a place­bo on the co-pri­maries — a 90% im­prove­ment in PASI 90 (the Pso­ri­a­sis Area and Sever­i­ty In­dex) and In­ves­ti­ga­tor Glob­al As­sess­ment (IGA) re­sponse of clear or al­most clear (IGA 0/1) at week 16, com­pared to place­bo. In­ves­ti­ga­tors al­so boast­ed of hit­ting some key sec­on­daries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.